| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aging | 95 | 2022 | 1019 | 15.190 |
Why?
|
| Oxidative Stress | 85 | 2022 | 677 | 11.630 |
Why?
|
| Endothelium, Vascular | 51 | 2021 | 334 | 9.850 |
Why?
|
| Neurovascular Coupling | 23 | 2022 | 154 | 7.450 |
Why?
|
| Cognitive Dysfunction | 26 | 2022 | 271 | 7.440 |
Why?
|
| Endothelial Cells | 33 | 2021 | 373 | 5.730 |
Why?
|
| Hypertension | 21 | 2021 | 309 | 5.660 |
Why?
|
| Cerebrovascular Circulation | 26 | 2022 | 224 | 5.390 |
Why?
|
| Animals | 198 | 2022 | 10703 | 5.160 |
Why?
|
| Stilbenes | 24 | 2016 | 91 | 5.070 |
Why?
|
| Antioxidants | 28 | 2019 | 224 | 4.470 |
Why?
|
| Longevity | 23 | 2022 | 141 | 4.460 |
Why?
|
| Mitochondria | 24 | 2020 | 410 | 4.000 |
Why?
|
| Insulin-Like Growth Factor I | 20 | 2019 | 301 | 3.890 |
Why?
|
| Reactive Oxygen Species | 36 | 2019 | 292 | 3.780 |
Why?
|
| Brain | 31 | 2022 | 770 | 3.650 |
Why?
|
| Microvessels | 14 | 2021 | 86 | 3.580 |
Why?
|
| Microcirculation | 15 | 2020 | 113 | 3.330 |
Why?
|
| Cognition | 17 | 2021 | 331 | 3.260 |
Why?
|
| NF-E2-Related Factor 2 | 16 | 2019 | 122 | 3.190 |
Why?
|
| Vasodilation | 23 | 2019 | 115 | 3.110 |
Why?
|
| Mice | 74 | 2022 | 4809 | 3.110 |
Why?
|
| Mice, Inbred C57BL | 54 | 2022 | 1659 | 3.070 |
Why?
|
| Cerebral Hemorrhage | 12 | 2022 | 93 | 2.930 |
Why?
|
| Vascular Diseases | 10 | 2019 | 68 | 2.840 |
Why?
|
| Cellular Senescence | 14 | 2022 | 141 | 2.740 |
Why?
|
| Coronary Vessels | 19 | 2012 | 154 | 2.570 |
Why?
|
| Blood-Brain Barrier | 12 | 2021 | 97 | 2.560 |
Why?
|
| Growth Hormone | 9 | 2022 | 103 | 2.560 |
Why?
|
| Neovascularization, Physiologic | 12 | 2019 | 124 | 2.550 |
Why?
|
| Rats | 61 | 2019 | 1590 | 2.520 |
Why?
|
| Inflammation | 24 | 2019 | 668 | 2.490 |
Why?
|
| Hyperemia | 4 | 2022 | 40 | 2.450 |
Why?
|
| Nicotinamide Mononucleotide | 4 | 2020 | 23 | 2.430 |
Why?
|
| Alzheimer Disease | 13 | 2021 | 225 | 2.400 |
Why?
|
| Disease Models, Animal | 46 | 2020 | 1508 | 2.250 |
Why?
|
| Male | 114 | 2022 | 13943 | 2.250 |
Why?
|
| Blood Vessels | 6 | 2020 | 58 | 2.120 |
Why?
|
| Muscle, Smooth, Vascular | 18 | 2018 | 77 | 2.090 |
Why?
|
| Tumor Necrosis Factor-alpha | 18 | 2019 | 251 | 1.920 |
Why?
|
| Arterioles | 23 | 2022 | 61 | 1.890 |
Why?
|
| Hydrogen Peroxide | 20 | 2019 | 145 | 1.890 |
Why?
|
| Cardiovascular Diseases | 8 | 2018 | 381 | 1.860 |
Why?
|
| Humans | 114 | 2022 | 28896 | 1.810 |
Why?
|
| NF-kappa B | 18 | 2017 | 191 | 1.800 |
Why?
|
| Nitric Oxide | 18 | 2019 | 153 | 1.770 |
Why?
|
| Caloric Restriction | 11 | 2016 | 74 | 1.760 |
Why?
|
| Aorta | 12 | 2019 | 124 | 1.750 |
Why?
|
| Cells, Cultured | 32 | 2017 | 1022 | 1.590 |
Why?
|
| Carotid Arteries | 8 | 2011 | 54 | 1.590 |
Why?
|
| Age Factors | 19 | 2021 | 737 | 1.510 |
Why?
|
| Apoptosis | 27 | 2018 | 780 | 1.510 |
Why?
|
| NADPH Oxidases | 16 | 2013 | 69 | 1.500 |
Why?
|
| Astrocytes | 6 | 2021 | 80 | 1.490 |
Why?
|
| Obesity | 11 | 2020 | 701 | 1.490 |
Why?
|
| Hippocampus | 14 | 2021 | 198 | 1.480 |
Why?
|
| Vasoconstriction | 8 | 2019 | 45 | 1.460 |
Why?
|
| DNA Damage | 6 | 2019 | 152 | 1.460 |
Why?
|
| Middle Cerebral Artery | 6 | 2021 | 54 | 1.420 |
Why?
|
| Rejuvenation | 3 | 2020 | 33 | 1.410 |
Why?
|
| Cognition Disorders | 7 | 2017 | 186 | 1.380 |
Why?
|
| Parabiosis | 2 | 2022 | 17 | 1.370 |
Why?
|
| Bone Morphogenetic Proteins | 6 | 2008 | 34 | 1.320 |
Why?
|
| Calcium | 12 | 2013 | 243 | 1.320 |
Why?
|
| Cardiovascular System | 7 | 2013 | 41 | 1.310 |
Why?
|
| Dementia, Vascular | 8 | 2021 | 57 | 1.250 |
Why?
|
| Pandemics | 3 | 2022 | 202 | 1.250 |
Why?
|
| Inflammation Mediators | 9 | 2018 | 169 | 1.200 |
Why?
|
| Rats, Wistar | 30 | 2019 | 153 | 1.190 |
Why?
|
| MicroRNAs | 4 | 2019 | 302 | 1.180 |
Why?
|
| Angiotensin II | 10 | 2021 | 55 | 1.160 |
Why?
|
| Dietary Supplements | 3 | 2020 | 273 | 1.120 |
Why?
|
| Superoxides | 12 | 2014 | 62 | 1.120 |
Why?
|
| Myocytes, Smooth Muscle | 5 | 2015 | 39 | 1.070 |
Why?
|
| Dementia | 3 | 2018 | 97 | 1.050 |
Why?
|
| Maze Learning | 8 | 2019 | 78 | 1.050 |
Why?
|
| Gait | 7 | 2021 | 61 | 1.050 |
Why?
|
| Aged | 30 | 2022 | 5599 | 1.040 |
Why?
|
| Sirtuin 1 | 7 | 2020 | 41 | 1.030 |
Why?
|
| Rats, Inbred F344 | 13 | 2019 | 174 | 1.000 |
Why?
|
| Diet, High-Fat | 7 | 2018 | 144 | 0.990 |
Why?
|
| Signal Transduction | 15 | 2019 | 1469 | 0.950 |
Why?
|
| Cerebral Cortex | 6 | 2021 | 136 | 0.950 |
Why?
|
| Gene Expression Regulation | 14 | 2019 | 634 | 0.930 |
Why?
|
| Blood Pressure | 11 | 2015 | 357 | 0.930 |
Why?
|
| Vasodilator Agents | 14 | 2013 | 79 | 0.920 |
Why?
|
| Cerebral Arteries | 6 | 2019 | 33 | 0.920 |
Why?
|
| Fibroblasts | 3 | 2017 | 160 | 0.900 |
Why?
|
| Peripheral Arterial Disease | 8 | 2022 | 144 | 0.890 |
Why?
|
| Arteries | 4 | 2018 | 66 | 0.890 |
Why?
|
| Cognitive Aging | 3 | 2020 | 22 | 0.890 |
Why?
|
| DNA Repair | 2 | 2017 | 82 | 0.880 |
Why?
|
| Cerebrovascular Disorders | 4 | 2018 | 46 | 0.860 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2012 | 78 | 0.850 |
Why?
|
| Zoonoses | 2 | 2021 | 13 | 0.840 |
Why?
|
| Adaptation, Physiological | 4 | 2015 | 173 | 0.830 |
Why?
|
| Serotonin Uptake Inhibitors | 8 | 2002 | 26 | 0.830 |
Why?
|
| Sirtuins | 5 | 2012 | 17 | 0.830 |
Why?
|
| Transcriptome | 3 | 2022 | 232 | 0.830 |
Why?
|
| Nitric Oxide Synthase Type III | 9 | 2016 | 55 | 0.820 |
Why?
|
| Cytokines | 10 | 2019 | 451 | 0.820 |
Why?
|
| RNA, Messenger | 12 | 2016 | 668 | 0.810 |
Why?
|
| Microvascular Rarefaction | 2 | 2021 | 13 | 0.810 |
Why?
|
| Homeostasis | 7 | 2016 | 119 | 0.790 |
Why?
|
| Geriatrics | 5 | 2020 | 47 | 0.790 |
Why?
|
| Liposomes | 3 | 2019 | 145 | 0.790 |
Why?
|
| Phenotype | 13 | 2021 | 686 | 0.790 |
Why?
|
| Sulfonamides | 3 | 2021 | 73 | 0.780 |
Why?
|
| Dwarfism, Pituitary | 1 | 2022 | 4 | 0.780 |
Why?
|
| Human Growth Hormone | 1 | 2022 | 15 | 0.770 |
Why?
|
| tert-Butylhydroperoxide | 2 | 2012 | 7 | 0.730 |
Why?
|
| Matrix Metalloproteinase 9 | 2 | 2021 | 54 | 0.730 |
Why?
|
| Hemodynamics | 5 | 2021 | 221 | 0.720 |
Why?
|
| Hyperglycemia | 4 | 2011 | 78 | 0.710 |
Why?
|
| NAD | 2 | 2019 | 104 | 0.710 |
Why?
|
| Healthy Aging | 1 | 2021 | 5 | 0.710 |
Why?
|
| Aniline Compounds | 1 | 2021 | 23 | 0.710 |
Why?
|
| Capillary Permeability | 2 | 2021 | 56 | 0.690 |
Why?
|
| Microscopy, Fluorescence, Multiphoton | 1 | 2021 | 8 | 0.690 |
Why?
|
| Intravital Microscopy | 1 | 2021 | 10 | 0.690 |
Why?
|
| Endothelium | 4 | 2020 | 28 | 0.680 |
Why?
|
| Dose-Response Relationship, Drug | 16 | 2019 | 612 | 0.680 |
Why?
|
| Protein Kinase C | 5 | 2006 | 74 | 0.680 |
Why?
|
| Neovascularization, Pathologic | 2 | 2017 | 148 | 0.670 |
Why?
|
| Biomarkers | 14 | 2022 | 777 | 0.670 |
Why?
|
| Cerebral Amyloid Angiopathy | 1 | 2020 | 6 | 0.670 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 6 | 0.660 |
Why?
|
| Lameness, Animal | 2 | 2017 | 8 | 0.660 |
Why?
|
| Nitric Oxide Synthase | 7 | 2012 | 34 | 0.660 |
Why?
|
| Anti-Inflammatory Agents | 6 | 2020 | 128 | 0.650 |
Why?
|
| Rats, Inbred BN | 6 | 2019 | 72 | 0.650 |
Why?
|
| Mice, Knockout | 15 | 2018 | 875 | 0.640 |
Why?
|
| Tomography, Optical Coherence | 1 | 2021 | 96 | 0.640 |
Why?
|
| Betacoronavirus | 1 | 2020 | 39 | 0.640 |
Why?
|
| Acetylcholine | 12 | 2010 | 73 | 0.630 |
Why?
|
| Hyperhomocysteinemia | 5 | 2003 | 29 | 0.630 |
Why?
|
| Sequence Analysis, RNA | 1 | 2020 | 58 | 0.630 |
Why?
|
| Phenanthrenes | 1 | 2019 | 10 | 0.630 |
Why?
|
| Vascular Resistance | 4 | 2009 | 50 | 0.630 |
Why?
|
| Risk Factors | 12 | 2020 | 2127 | 0.630 |
Why?
|
| Smoking | 3 | 2009 | 478 | 0.620 |
Why?
|
| Muscle, Skeletal | 12 | 2018 | 641 | 0.620 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 49 | 0.620 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 53 | 0.620 |
Why?
|
| TRPC Cation Channels | 3 | 2014 | 34 | 0.610 |
Why?
|
| Hydroxyeicosatetraenoic Acids | 3 | 2013 | 16 | 0.610 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 49 | 0.610 |
Why?
|
| Female | 39 | 2022 | 15646 | 0.610 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 1 | 2019 | 15 | 0.610 |
Why?
|
| Extracellular Matrix | 2 | 2017 | 117 | 0.600 |
Why?
|
| Enzyme Inhibitors | 14 | 2019 | 251 | 0.600 |
Why?
|
| Cerebral Veins | 1 | 2019 | 11 | 0.600 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2019 | 38 | 0.590 |
Why?
|
| Brain Injuries, Traumatic | 4 | 2021 | 46 | 0.590 |
Why?
|
| Intracranial Hemorrhages | 3 | 2015 | 32 | 0.590 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2019 | 48 | 0.590 |
Why?
|
| Valsalva Maneuver | 1 | 2018 | 8 | 0.580 |
Why?
|
| Bone Morphogenetic Protein 4 | 5 | 2009 | 14 | 0.570 |
Why?
|
| Pulmonary Artery | 2 | 2009 | 69 | 0.570 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2018 | 43 | 0.560 |
Why?
|
| Models, Biological | 6 | 2012 | 469 | 0.560 |
Why?
|
| Up-Regulation | 9 | 2013 | 247 | 0.560 |
Why?
|
| Intercellular Adhesion Molecule-1 | 8 | 2012 | 59 | 0.560 |
Why?
|
| Diabetes Mellitus, Experimental | 4 | 2011 | 98 | 0.550 |
Why?
|
| Down-Regulation | 5 | 2016 | 202 | 0.540 |
Why?
|
| Gene Expression Profiling | 5 | 2019 | 465 | 0.540 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2017 | 9 | 0.540 |
Why?
|
| Sepsis | 1 | 2018 | 86 | 0.540 |
Why?
|
| Amyloid beta-Peptides | 3 | 2020 | 49 | 0.530 |
Why?
|
| Behavior, Animal | 5 | 2019 | 108 | 0.530 |
Why?
|
| Radiation Injuries, Experimental | 1 | 2017 | 31 | 0.510 |
Why?
|
| Transforming Growth Factor beta | 3 | 2006 | 79 | 0.510 |
Why?
|
| Transcription, Genetic | 8 | 2016 | 404 | 0.510 |
Why?
|
| Glucose | 5 | 2011 | 209 | 0.500 |
Why?
|
| Calcium Signaling | 4 | 2020 | 72 | 0.500 |
Why?
|
| Dwarfism | 4 | 2014 | 27 | 0.490 |
Why?
|
| Oxygen | 5 | 2012 | 237 | 0.480 |
Why?
|
| Receptors, Purinergic P2Y1 | 1 | 2015 | 4 | 0.480 |
Why?
|
| Bone Morphogenetic Protein 2 | 4 | 2009 | 30 | 0.480 |
Why?
|
| Bivalvia | 2 | 2012 | 20 | 0.470 |
Why?
|
| Somatosensory Cortex | 1 | 2015 | 17 | 0.470 |
Why?
|
| Energy Metabolism | 3 | 2019 | 216 | 0.470 |
Why?
|
| Chronic Disease | 1 | 2016 | 274 | 0.470 |
Why?
|
| Life Expectancy | 3 | 2012 | 23 | 0.470 |
Why?
|
| Cell Proliferation | 10 | 2019 | 825 | 0.470 |
Why?
|
| Cell Adhesion | 8 | 2014 | 139 | 0.460 |
Why?
|
| Peptides | 1 | 2018 | 296 | 0.460 |
Why?
|
| Pulsatile Flow | 1 | 2015 | 9 | 0.460 |
Why?
|
| Mercenaria | 2 | 2013 | 6 | 0.450 |
Why?
|
| Cell Communication | 1 | 2015 | 68 | 0.450 |
Why?
|
| Fluoxetine | 6 | 2001 | 11 | 0.450 |
Why?
|
| Renin-Angiotensin System | 4 | 2013 | 18 | 0.450 |
Why?
|
| Biological Factors | 3 | 2010 | 12 | 0.450 |
Why?
|
| NG-Nitroarginine Methyl Ester | 7 | 2019 | 31 | 0.440 |
Why?
|
| Pituitary Adenylate Cyclase-Activating Polypeptide | 1 | 2014 | 7 | 0.440 |
Why?
|
| Models, Immunological | 2 | 2004 | 22 | 0.430 |
Why?
|
| Thromboxane A2 | 4 | 2002 | 5 | 0.420 |
Why?
|
| Rats, Inbred Lew | 5 | 2017 | 34 | 0.420 |
Why?
|
| Cerebrum | 1 | 2013 | 14 | 0.420 |
Why?
|
| Large-Conductance Calcium-Activated Potassium Channel alpha Subunits | 1 | 2013 | 4 | 0.410 |
Why?
|
| Potassium Channels | 4 | 2002 | 20 | 0.410 |
Why?
|
| Diabetes Mellitus, Type 2 | 5 | 2010 | 344 | 0.400 |
Why?
|
| Oxidation-Reduction | 6 | 2018 | 381 | 0.400 |
Why?
|
| Cell Physiological Phenomena | 1 | 2013 | 7 | 0.400 |
Why?
|
| Muscle, Smooth | 3 | 2022 | 41 | 0.400 |
Why?
|
| Mole Rats | 3 | 2008 | 6 | 0.400 |
Why?
|
| Gamma Rays | 1 | 2013 | 27 | 0.400 |
Why?
|
| Stroke | 2 | 2022 | 261 | 0.400 |
Why?
|
| Vasoconstrictor Agents | 9 | 2014 | 35 | 0.390 |
Why?
|
| Primates | 2 | 2014 | 22 | 0.390 |
Why?
|
| Ribonuclease III | 1 | 2012 | 6 | 0.390 |
Why?
|
| NAD(P)H Dehydrogenase (Quinone) | 7 | 2011 | 40 | 0.390 |
Why?
|
| Protein Carbonylation | 1 | 2012 | 6 | 0.380 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2012 | 26 | 0.380 |
Why?
|
| Mice, Transgenic | 8 | 2021 | 513 | 0.380 |
Why?
|
| Tissue Culture Techniques | 5 | 2015 | 31 | 0.380 |
Why?
|
| Shock, Septic | 1 | 2012 | 38 | 0.380 |
Why?
|
| Vascular Endothelial Growth Factor A | 7 | 2014 | 179 | 0.380 |
Why?
|
| In Vitro Techniques | 12 | 2003 | 242 | 0.380 |
Why?
|
| Catalase | 5 | 2019 | 49 | 0.370 |
Why?
|
| Gap Junctions | 2 | 2002 | 5 | 0.370 |
Why?
|
| Homocysteine | 3 | 2001 | 30 | 0.370 |
Why?
|
| Bacteremia | 1 | 2012 | 81 | 0.370 |
Why?
|
| Immunoglobulin G | 2 | 2019 | 272 | 0.370 |
Why?
|
| Muscle Contraction | 6 | 2018 | 171 | 0.360 |
Why?
|
| Spectroscopy, Near-Infrared | 3 | 2021 | 75 | 0.360 |
Why?
|
| Radiation Injuries | 3 | 2020 | 52 | 0.360 |
Why?
|
| Time Factors | 9 | 2021 | 1613 | 0.360 |
Why?
|
| Arteriosclerosis | 3 | 2007 | 30 | 0.350 |
Why?
|
| Platelet Aggregation | 4 | 2007 | 44 | 0.350 |
Why?
|
| Rabbits | 16 | 2018 | 278 | 0.350 |
Why?
|
| Atherosclerosis | 3 | 2019 | 97 | 0.340 |
Why?
|
| Free Radicals | 1 | 2011 | 39 | 0.340 |
Why?
|
| Adipose Tissue | 1 | 2012 | 197 | 0.340 |
Why?
|
| White Matter | 2 | 2022 | 90 | 0.340 |
Why?
|
| Species Specificity | 5 | 2013 | 195 | 0.330 |
Why?
|
| Cell Movement | 4 | 2019 | 376 | 0.330 |
Why?
|
| RNA, Small Interfering | 4 | 2019 | 198 | 0.330 |
Why?
|
| Gene Expression | 7 | 2018 | 417 | 0.330 |
Why?
|
| Nitric Oxide Synthase Type II | 5 | 2009 | 40 | 0.320 |
Why?
|
| Superoxide Dismutase | 7 | 2013 | 71 | 0.320 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 8 | 2010 | 328 | 0.310 |
Why?
|
| Neuroprotective Agents | 4 | 2019 | 52 | 0.310 |
Why?
|
| Vasculitis | 2 | 2011 | 13 | 0.310 |
Why?
|
| Reactive Nitrogen Species | 2 | 2009 | 10 | 0.310 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2011 | 125 | 0.300 |
Why?
|
| Neoplasms | 2 | 2017 | 874 | 0.300 |
Why?
|
| Macaca mulatta | 4 | 2016 | 50 | 0.300 |
Why?
|
| Motor Activity | 3 | 2019 | 148 | 0.300 |
Why?
|
| Blood Platelets | 2 | 2002 | 206 | 0.300 |
Why?
|
| Random Allocation | 3 | 2019 | 151 | 0.300 |
Why?
|
| Hypertension, Pulmonary | 1 | 2009 | 34 | 0.300 |
Why?
|
| Middle Aged | 14 | 2022 | 7416 | 0.300 |
Why?
|
| Retinal Artery | 2 | 2019 | 10 | 0.300 |
Why?
|
| Mechanotransduction, Cellular | 3 | 2015 | 27 | 0.290 |
Why?
|
| Aspirin | 3 | 2007 | 125 | 0.290 |
Why?
|
| Risk Assessment | 4 | 2020 | 631 | 0.290 |
Why?
|
| Glycation End Products, Advanced | 1 | 2008 | 17 | 0.290 |
Why?
|
| Blotting, Western | 11 | 2010 | 515 | 0.290 |
Why?
|
| Tobacco | 1 | 2009 | 87 | 0.280 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2006 | 191 | 0.280 |
Why?
|
| Transfection | 4 | 2017 | 319 | 0.280 |
Why?
|
| Memory Disorders | 2 | 2019 | 50 | 0.280 |
Why?
|
| Glutamate-Cysteine Ligase | 4 | 2011 | 25 | 0.280 |
Why?
|
| Diabetic Angiopathies | 1 | 2008 | 48 | 0.280 |
Why?
|
| Vasomotor System | 2 | 2013 | 8 | 0.280 |
Why?
|
| Receptors, Immunologic | 1 | 2008 | 73 | 0.280 |
Why?
|
| Femoral Artery | 2 | 2010 | 58 | 0.280 |
Why?
|
| Smoke | 1 | 2008 | 37 | 0.270 |
Why?
|
| Interleukin-6 | 4 | 2011 | 198 | 0.270 |
Why?
|
| Epigenesis, Genetic | 2 | 2019 | 148 | 0.270 |
Why?
|
| Mitochondrial Proteins | 1 | 2008 | 80 | 0.270 |
Why?
|
| Oxidoreductases | 2 | 2007 | 57 | 0.270 |
Why?
|
| Cortical Spreading Depression | 2 | 2017 | 2 | 0.260 |
Why?
|
| Penicillamine | 2 | 2004 | 9 | 0.260 |
Why?
|
| Matrix Metalloproteinases | 2 | 2017 | 31 | 0.260 |
Why?
|
| Arteritis | 1 | 2007 | 3 | 0.260 |
Why?
|
| Tars | 1 | 2007 | 5 | 0.260 |
Why?
|
| Sensitivity and Specificity | 3 | 2017 | 524 | 0.260 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2007 | 36 | 0.260 |
Why?
|
| Pregnancy | 8 | 2017 | 1259 | 0.250 |
Why?
|
| Microglia | 2 | 2019 | 69 | 0.250 |
Why?
|
| Cyclic AMP | 1 | 2007 | 96 | 0.250 |
Why?
|
| Premature Birth | 4 | 2017 | 58 | 0.250 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2021 | 841 | 0.250 |
Why?
|
| Animals, Newborn | 6 | 2017 | 182 | 0.240 |
Why?
|
| Memory, Short-Term | 3 | 2021 | 64 | 0.240 |
Why?
|
| Recovery of Function | 3 | 2016 | 123 | 0.230 |
Why?
|
| Caspase 3 | 3 | 2014 | 58 | 0.230 |
Why?
|
| Forecasting | 2 | 2021 | 76 | 0.230 |
Why?
|
| Exercise Tolerance | 2 | 2017 | 82 | 0.230 |
Why?
|
| Endothelins | 2 | 2006 | 7 | 0.230 |
Why?
|
| Tyrosine | 2 | 2002 | 92 | 0.230 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2005 | 22 | 0.230 |
Why?
|
| Sex Characteristics | 2 | 2017 | 175 | 0.230 |
Why?
|
| Myocardium | 3 | 2014 | 196 | 0.230 |
Why?
|
| Kidney | 1 | 2007 | 289 | 0.230 |
Why?
|
| Heart Failure | 3 | 2014 | 253 | 0.230 |
Why?
|
| Interleukins | 2 | 2019 | 112 | 0.220 |
Why?
|
| RNA Interference | 3 | 2010 | 137 | 0.220 |
Why?
|
| Sleep Deprivation | 2 | 2021 | 28 | 0.220 |
Why?
|
| Gene Knockdown Techniques | 3 | 2014 | 134 | 0.220 |
Why?
|
| Aged, 80 and over | 5 | 2022 | 2065 | 0.220 |
Why?
|
| Dogs | 4 | 2021 | 510 | 0.220 |
Why?
|
| Antidepressive Agents, Second-Generation | 2 | 2001 | 6 | 0.220 |
Why?
|
| Neurons | 4 | 2021 | 297 | 0.220 |
Why?
|
| NADH, NADPH Oxidoreductases | 2 | 2003 | 11 | 0.220 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2019 | 554 | 0.210 |
Why?
|
| Coronary Artery Disease | 2 | 2004 | 220 | 0.210 |
Why?
|
| Caveolin 1 | 2 | 2018 | 43 | 0.210 |
Why?
|
| Regional Blood Flow | 3 | 2019 | 164 | 0.210 |
Why?
|
| Leukoencephalopathies | 2 | 2021 | 5 | 0.210 |
Why?
|
| Organ Culture Techniques | 3 | 2012 | 56 | 0.210 |
Why?
|
| Monocytes | 4 | 2014 | 135 | 0.210 |
Why?
|
| Public Health | 2 | 2022 | 97 | 0.210 |
Why?
|
| Interleukin-17 | 1 | 2004 | 52 | 0.210 |
Why?
|
| Dietary Fats | 4 | 2011 | 59 | 0.200 |
Why?
|
| Mice, Inbred ICR | 3 | 2018 | 26 | 0.200 |
Why?
|
| Phenanthridines | 3 | 2012 | 12 | 0.200 |
Why?
|
| Recombinant Proteins | 3 | 2018 | 416 | 0.200 |
Why?
|
| Motion Pictures | 1 | 2022 | 4 | 0.200 |
Why?
|
| Enzyme Activation | 4 | 2007 | 267 | 0.190 |
Why?
|
| Liver | 5 | 2016 | 471 | 0.190 |
Why?
|
| Coronary Circulation | 1 | 2002 | 30 | 0.190 |
Why?
|
| Models, Animal | 3 | 2018 | 130 | 0.190 |
Why?
|
| Isoprostanes | 1 | 2002 | 3 | 0.190 |
Why?
|
| Heme Oxygenase-1 | 3 | 2011 | 36 | 0.190 |
Why?
|
| Endothelial Growth Factors | 1 | 2002 | 6 | 0.180 |
Why?
|
| Lymphokines | 1 | 2002 | 8 | 0.180 |
Why?
|
| Analysis of Variance | 5 | 2016 | 391 | 0.180 |
Why?
|
| Simvastatin | 1 | 2002 | 24 | 0.180 |
Why?
|
| Memory | 3 | 2017 | 76 | 0.180 |
Why?
|
| Neuronal Plasticity | 2 | 2019 | 51 | 0.180 |
Why?
|
| Ferrets | 1 | 2021 | 4 | 0.180 |
Why?
|
| Hip Fractures | 1 | 2001 | 10 | 0.180 |
Why?
|
| Ion Channels | 1 | 2001 | 28 | 0.180 |
Why?
|
| Cats | 1 | 2021 | 52 | 0.180 |
Why?
|
| 8,11,14-Eicosatrienoic Acid | 1 | 2001 | 5 | 0.180 |
Why?
|
| Stem Cells | 2 | 2014 | 123 | 0.180 |
Why?
|
| Accidental Falls | 1 | 2001 | 32 | 0.180 |
Why?
|
| Public Health Practice | 1 | 2021 | 13 | 0.180 |
Why?
|
| Intracellular Fluid | 1 | 2001 | 12 | 0.180 |
Why?
|
| bcl-X Protein | 1 | 2021 | 35 | 0.180 |
Why?
|
| Pentose Phosphate Pathway | 3 | 2014 | 12 | 0.180 |
Why?
|
| Dinoprostone | 2 | 2019 | 42 | 0.180 |
Why?
|
| Insulin | 3 | 2012 | 325 | 0.170 |
Why?
|
| Biological Evolution | 2 | 2012 | 101 | 0.170 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2002 | 77 | 0.170 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2021 | 41 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2021 | 68 | 0.170 |
Why?
|
| Peromyscus | 3 | 2013 | 7 | 0.170 |
Why?
|
| Motor Cortex | 1 | 2021 | 48 | 0.170 |
Why?
|
| Prostaglandins H | 1 | 2000 | 1 | 0.170 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2013 | 163 | 0.170 |
Why?
|
| Prognosis | 3 | 2020 | 811 | 0.170 |
Why?
|
| Indomethacin | 2 | 2017 | 15 | 0.170 |
Why?
|
| Kelch-Like ECH-Associated Protein 1 | 2 | 2011 | 15 | 0.170 |
Why?
|
| Cyclooxygenase Inhibitors | 2 | 2017 | 25 | 0.170 |
Why?
|
| Immunohistochemistry | 7 | 2010 | 465 | 0.170 |
Why?
|
| Swimming | 2 | 2018 | 32 | 0.170 |
Why?
|
| Infant, Premature | 3 | 2018 | 149 | 0.170 |
Why?
|
| Muscle Tonus | 1 | 2000 | 2 | 0.160 |
Why?
|
| Cardiotonic Agents | 2 | 2014 | 28 | 0.160 |
Why?
|
| Reference Values | 2 | 2019 | 200 | 0.160 |
Why?
|
| Nerve Fibers, Myelinated | 2 | 2018 | 22 | 0.160 |
Why?
|
| TRPM Cation Channels | 1 | 2020 | 9 | 0.160 |
Why?
|
| Kangai-1 Protein | 1 | 2020 | 8 | 0.160 |
Why?
|
| Preventive Medicine | 1 | 2020 | 14 | 0.160 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2013 | 129 | 0.160 |
Why?
|
| Spatial Learning | 1 | 2019 | 6 | 0.160 |
Why?
|
| Rest | 1 | 2020 | 96 | 0.160 |
Why?
|
| Wet Macular Degeneration | 1 | 2019 | 9 | 0.160 |
Why?
|
| Choroid | 1 | 2019 | 21 | 0.160 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2010 | 131 | 0.150 |
Why?
|
| Betamethasone | 2 | 2010 | 14 | 0.150 |
Why?
|
| Paracrine Communication | 2 | 2012 | 17 | 0.150 |
Why?
|
| Calcium Channels | 1 | 1999 | 34 | 0.150 |
Why?
|
| Methionine | 1 | 1999 | 38 | 0.150 |
Why?
|
| Chemokines | 1 | 2019 | 74 | 0.150 |
Why?
|
| Psychomotor Disorders | 1 | 2019 | 5 | 0.150 |
Why?
|
| Nerve Tissue Proteins | 3 | 2020 | 154 | 0.150 |
Why?
|
| Spatial Memory | 2 | 2018 | 16 | 0.150 |
Why?
|
| Cytoprotection | 2 | 2010 | 24 | 0.150 |
Why?
|
| Rodentia | 1 | 2019 | 14 | 0.150 |
Why?
|
| Photic Stimulation | 1 | 2019 | 71 | 0.150 |
Why?
|
| Quality of Life | 2 | 2021 | 521 | 0.150 |
Why?
|
| Eicosanoids | 1 | 2019 | 10 | 0.150 |
Why?
|
| Myocardial Infarction | 1 | 2002 | 351 | 0.150 |
Why?
|
| Retinal Vessels | 1 | 2019 | 75 | 0.150 |
Why?
|
| Visual Perception | 1 | 2019 | 45 | 0.150 |
Why?
|
| Brain Concussion | 1 | 2019 | 53 | 0.150 |
Why?
|
| Oligopeptides | 1 | 2019 | 97 | 0.150 |
Why?
|
| Vascular Stiffness | 1 | 2019 | 41 | 0.150 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2019 | 64 | 0.150 |
Why?
|
| Carcinogenesis | 1 | 2019 | 81 | 0.150 |
Why?
|
| Walking | 2 | 2017 | 136 | 0.150 |
Why?
|
| Proteostasis | 1 | 2018 | 9 | 0.150 |
Why?
|
| Aminoimidazole Carboxamide | 1 | 2018 | 7 | 0.150 |
Why?
|
| Ribonucleotides | 1 | 2018 | 7 | 0.150 |
Why?
|
| Rats, Inbred SHR | 4 | 2019 | 13 | 0.150 |
Why?
|
| Ligation | 1 | 2018 | 39 | 0.140 |
Why?
|
| Research | 1 | 2019 | 93 | 0.140 |
Why?
|
| Cecum | 1 | 2018 | 14 | 0.140 |
Why?
|
| Punctures | 1 | 2018 | 17 | 0.140 |
Why?
|
| Amyloid beta-Protein Precursor | 2 | 2021 | 34 | 0.140 |
Why?
|
| Wnt3A Protein | 1 | 2018 | 6 | 0.140 |
Why?
|
| Transcriptional Activation | 2 | 2010 | 86 | 0.140 |
Why?
|
| Genomic Instability | 1 | 2018 | 34 | 0.140 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2018 | 42 | 0.140 |
Why?
|
| Cerebral Ventricles | 4 | 2016 | 17 | 0.140 |
Why?
|
| Exercise Test | 5 | 2017 | 249 | 0.140 |
Why?
|
| Norepinephrine | 5 | 2002 | 32 | 0.140 |
Why?
|
| 6-Aminonicotinamide | 3 | 2014 | 3 | 0.140 |
Why?
|
| Neurogenesis | 1 | 2017 | 22 | 0.140 |
Why?
|
| Circadian Rhythm | 1 | 2018 | 76 | 0.140 |
Why?
|
| Interneurons | 1 | 2017 | 25 | 0.140 |
Why?
|
| Estrogens | 1 | 2017 | 56 | 0.130 |
Why?
|
| Physiology | 1 | 2017 | 8 | 0.130 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2017 | 23 | 0.130 |
Why?
|
| Genetic Pleiotropy | 1 | 2017 | 9 | 0.130 |
Why?
|
| S-Nitroso-N-Acetylpenicillamine | 3 | 2010 | 6 | 0.130 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2017 | 82 | 0.130 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2017 | 10 | 0.130 |
Why?
|
| Cell Culture Techniques | 2 | 2017 | 117 | 0.130 |
Why?
|
| Sirolimus | 1 | 2017 | 76 | 0.130 |
Why?
|
| Vascular Remodeling | 1 | 2017 | 14 | 0.130 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 429 | 0.130 |
Why?
|
| Brain Ischemia | 2 | 2016 | 87 | 0.130 |
Why?
|
| Drug Delivery Systems | 1 | 2019 | 236 | 0.130 |
Why?
|
| Amyloid Precursor Protein Secretases | 2 | 2013 | 25 | 0.130 |
Why?
|
| Periodicals as Topic | 1 | 2017 | 53 | 0.130 |
Why?
|
| Psychomotor Performance | 1 | 2017 | 72 | 0.130 |
Why?
|
| Drug Resistance | 3 | 2007 | 42 | 0.130 |
Why?
|
| Neocortex | 1 | 2016 | 9 | 0.130 |
Why?
|
| Exercise | 2 | 2012 | 498 | 0.130 |
Why?
|
| Heart Diseases | 2 | 2007 | 71 | 0.120 |
Why?
|
| United States | 2 | 2020 | 2226 | 0.120 |
Why?
|
| Dietary Sucrose | 1 | 2016 | 7 | 0.120 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2017 | 166 | 0.120 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2014 | 56 | 0.120 |
Why?
|
| Prospective Studies | 4 | 2022 | 1280 | 0.120 |
Why?
|
| Receptors, AMPA | 1 | 2016 | 8 | 0.120 |
Why?
|
| Infant, Newborn | 7 | 2018 | 916 | 0.120 |
Why?
|
| Adult | 7 | 2022 | 8035 | 0.120 |
Why?
|
| Health Status | 1 | 2017 | 149 | 0.120 |
Why?
|
| Stress, Mechanical | 2 | 2007 | 115 | 0.120 |
Why?
|
| Nitric Oxide Donors | 2 | 2007 | 11 | 0.120 |
Why?
|
| Exercise Therapy | 1 | 2017 | 84 | 0.120 |
Why?
|
| Nervous System Diseases | 1 | 2016 | 40 | 0.120 |
Why?
|
| Immunomagnetic Separation | 1 | 2015 | 4 | 0.120 |
Why?
|
| Purinergic P2Y Receptor Agonists | 1 | 2015 | 4 | 0.120 |
Why?
|
| Membrane Fusion | 1 | 2015 | 7 | 0.120 |
Why?
|
| Vibrissae | 1 | 2015 | 6 | 0.120 |
Why?
|
| 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester | 3 | 2000 | 7 | 0.120 |
Why?
|
| Calcium Channel Agonists | 3 | 2000 | 7 | 0.120 |
Why?
|
| Diabetic Retinopathy | 1 | 2017 | 112 | 0.120 |
Why?
|
| Muscle Cells | 1 | 2015 | 15 | 0.120 |
Why?
|
| Heat-Shock Proteins | 2 | 2013 | 38 | 0.120 |
Why?
|
| Biotin | 1 | 2015 | 25 | 0.120 |
Why?
|
| Biomedical Research | 1 | 2016 | 98 | 0.120 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2015 | 34 | 0.120 |
Why?
|
| Cell Separation | 1 | 2015 | 57 | 0.120 |
Why?
|
| Microscopy, Fluorescence | 2 | 2009 | 163 | 0.110 |
Why?
|
| Rats, Mutant Strains | 2 | 2014 | 16 | 0.110 |
Why?
|
| Pericytes | 3 | 2014 | 17 | 0.110 |
Why?
|
| Depression | 2 | 2011 | 225 | 0.110 |
Why?
|
| Membrane Proteins | 3 | 2020 | 485 | 0.110 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 2 | 2012 | 11 | 0.110 |
Why?
|
| Fluorescent Dyes | 3 | 2009 | 93 | 0.110 |
Why?
|
| Acetophenones | 4 | 2010 | 9 | 0.110 |
Why?
|
| Mice, 129 Strain | 1 | 2014 | 9 | 0.110 |
Why?
|
| Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide | 1 | 2014 | 5 | 0.110 |
Why?
|
| Spine | 1 | 2015 | 63 | 0.110 |
Why?
|
| Encephalitis | 1 | 2014 | 18 | 0.110 |
Why?
|
| Bone Density | 1 | 2015 | 101 | 0.110 |
Why?
|
| Endothelin-1 | 1 | 2014 | 10 | 0.110 |
Why?
|
| Cell Differentiation | 1 | 2017 | 427 | 0.110 |
Why?
|
| Electron Transport Complex IV | 3 | 2013 | 40 | 0.110 |
Why?
|
| Glucose Tolerance Test | 2 | 2011 | 60 | 0.110 |
Why?
|
| Models, Neurological | 1 | 2014 | 35 | 0.110 |
Why?
|
| Cell Line | 2 | 2017 | 700 | 0.110 |
Why?
|
| Crosses, Genetic | 1 | 2014 | 36 | 0.110 |
Why?
|
| Free Radical Scavengers | 2 | 2012 | 23 | 0.110 |
Why?
|
| Whole-Body Irradiation | 1 | 2014 | 40 | 0.110 |
Why?
|
| Sucrose | 1 | 2014 | 27 | 0.110 |
Why?
|
| Pharmaceutical Vehicles | 1 | 2014 | 7 | 0.110 |
Why?
|
| Glutathione Peroxidase | 2 | 2013 | 26 | 0.110 |
Why?
|
| Hemorrhage | 1 | 2016 | 266 | 0.110 |
Why?
|
| Lower Extremity | 1 | 2015 | 85 | 0.110 |
Why?
|
| Disease Progression | 2 | 2019 | 477 | 0.100 |
Why?
|
| Brain Injuries | 1 | 2014 | 50 | 0.100 |
Why?
|
| Mitochondria, Heart | 1 | 2013 | 26 | 0.100 |
Why?
|
| Cranial Irradiation | 1 | 2013 | 12 | 0.100 |
Why?
|
| Blood Glucose | 2 | 2014 | 310 | 0.100 |
Why?
|
| Receptor, Muscarinic M1 | 1 | 2013 | 5 | 0.100 |
Why?
|
| TRPC6 Cation Channel | 1 | 2013 | 6 | 0.100 |
Why?
|
| Serum Amyloid P-Component | 1 | 2013 | 9 | 0.100 |
Why?
|
| Homeodomain Proteins | 2 | 2017 | 79 | 0.100 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2011 | 94 | 0.100 |
Why?
|
| Genes, p16 | 1 | 2013 | 7 | 0.100 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2013 | 80 | 0.100 |
Why?
|
| Secretory Pathway | 1 | 2013 | 6 | 0.100 |
Why?
|
| beta-Galactosidase | 1 | 2013 | 24 | 0.100 |
Why?
|
| 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 3 | 2003 | 4 | 0.100 |
Why?
|
| Amidines | 1 | 2013 | 8 | 0.100 |
Why?
|
| Antihypertensive Agents | 1 | 2013 | 56 | 0.100 |
Why?
|
| Membrane Glycoproteins | 3 | 2010 | 149 | 0.100 |
Why?
|
| Chondroitin Sulfate Proteoglycans | 1 | 2013 | 7 | 0.100 |
Why?
|
| Actins | 1 | 2013 | 99 | 0.100 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 2 | 2010 | 19 | 0.100 |
Why?
|
| Caspase 8 | 1 | 2012 | 10 | 0.100 |
Why?
|
| Mice, Obese | 1 | 2012 | 22 | 0.100 |
Why?
|
| Tissue Survival | 1 | 2012 | 4 | 0.100 |
Why?
|
| Multiple Organ Failure | 1 | 2012 | 31 | 0.100 |
Why?
|
| Enzyme Induction | 2 | 2009 | 28 | 0.100 |
Why?
|
| Prosencephalon | 1 | 2012 | 7 | 0.100 |
Why?
|
| Laron Syndrome | 1 | 2012 | 2 | 0.090 |
Why?
|
| Seawater | 1 | 2012 | 42 | 0.090 |
Why?
|
| Mice, Mutant Strains | 2 | 2010 | 58 | 0.090 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2012 | 37 | 0.090 |
Why?
|
| Haplorhini | 1 | 2012 | 15 | 0.090 |
Why?
|
| Infant, Premature, Diseases | 1 | 2012 | 37 | 0.090 |
Why?
|
| Hominidae | 1 | 2012 | 11 | 0.090 |
Why?
|
| Culture Media, Conditioned | 1 | 2012 | 31 | 0.090 |
Why?
|
| African Americans | 1 | 2014 | 352 | 0.090 |
Why?
|
| Chemokine CCL2 | 2 | 2009 | 47 | 0.090 |
Why?
|
| Temperature | 1 | 2012 | 213 | 0.090 |
Why?
|
| Lipoproteins, LDL | 2 | 2011 | 42 | 0.090 |
Why?
|
| Glutathione | 2 | 2009 | 76 | 0.090 |
Why?
|
| Heme Oxygenase (Decyclizing) | 1 | 2011 | 12 | 0.090 |
Why?
|
| Nuclear Proteins | 1 | 2013 | 249 | 0.090 |
Why?
|
| Microscopy, Electron, Transmission | 2 | 2009 | 82 | 0.090 |
Why?
|
| Oxidants | 1 | 2011 | 31 | 0.090 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2012 | 120 | 0.090 |
Why?
|
| Somatomedins | 1 | 2011 | 18 | 0.090 |
Why?
|
| Physiology, Comparative | 1 | 2010 | 2 | 0.080 |
Why?
|
| Acetylcysteine | 1 | 2011 | 24 | 0.080 |
Why?
|
| Guinea Pigs | 3 | 2006 | 73 | 0.080 |
Why?
|
| Cytoskeletal Proteins | 1 | 2011 | 42 | 0.080 |
Why?
|
| Ascorbic Acid | 1 | 2010 | 24 | 0.080 |
Why?
|
| Receptors, Prostaglandin E | 1 | 2010 | 6 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor B | 1 | 2010 | 2 | 0.080 |
Why?
|
| Quinazolines | 2 | 2007 | 32 | 0.080 |
Why?
|
| Glutathione Synthase | 1 | 2010 | 4 | 0.080 |
Why?
|
| Microscopy, Video | 2 | 2000 | 18 | 0.080 |
Why?
|
| Large-Conductance Calcium-Activated Potassium Channels | 1 | 2010 | 2 | 0.080 |
Why?
|
| Response Elements | 1 | 2010 | 22 | 0.080 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2010 | 17 | 0.080 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 2 | 2007 | 23 | 0.080 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2010 | 64 | 0.080 |
Why?
|
| Polyethylene Glycols | 1 | 2011 | 101 | 0.080 |
Why?
|
| Genes, Reporter | 1 | 2010 | 87 | 0.080 |
Why?
|
| Piperidines | 2 | 2007 | 48 | 0.080 |
Why?
|
| Cardiomyopathies | 1 | 2010 | 33 | 0.080 |
Why?
|
| Resuscitation | 1 | 2010 | 59 | 0.080 |
Why?
|
| Case-Control Studies | 2 | 2021 | 739 | 0.080 |
Why?
|
| Lateral Ventricles | 1 | 2009 | 8 | 0.080 |
Why?
|
| Monocrotaline | 1 | 2009 | 4 | 0.080 |
Why?
|
| Tumor Necrosis Factors | 1 | 2009 | 15 | 0.080 |
Why?
|
| Body Weight | 1 | 2010 | 250 | 0.080 |
Why?
|
| Ankle Brachial Index | 2 | 2021 | 34 | 0.080 |
Why?
|
| ADAM17 Protein | 2 | 2006 | 13 | 0.080 |
Why?
|
| Electron Transport | 1 | 2009 | 31 | 0.080 |
Why?
|
| Young Adult | 3 | 2022 | 2839 | 0.080 |
Why?
|
| Glucosephosphate Dehydrogenase | 1 | 2009 | 5 | 0.080 |
Why?
|
| Nitrosation | 1 | 2009 | 4 | 0.070 |
Why?
|
| Neuropsychological Tests | 2 | 2021 | 249 | 0.070 |
Why?
|
| Citric Acid Cycle | 1 | 2008 | 16 | 0.070 |
Why?
|
| Biosensing Techniques | 1 | 2009 | 48 | 0.070 |
Why?
|
| Brain Mapping | 2 | 2021 | 207 | 0.070 |
Why?
|
| Hyperoxia | 1 | 2010 | 95 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2006 | 23 | 0.070 |
Why?
|
| DNA, Mitochondrial | 1 | 2009 | 85 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 2 | 2006 | 22 | 0.070 |
Why?
|
| src-Family Kinases | 1 | 2009 | 71 | 0.070 |
Why?
|
| Aorta, Thoracic | 1 | 2009 | 55 | 0.070 |
Why?
|
| ADAM Proteins | 2 | 2006 | 103 | 0.070 |
Why?
|
| Bone Morphogenetic Protein Receptors | 1 | 2008 | 4 | 0.070 |
Why?
|
| Receptor for Advanced Glycation End Products | 1 | 2008 | 12 | 0.070 |
Why?
|
| Early Diagnosis | 2 | 2020 | 32 | 0.070 |
Why?
|
| Heparan Sulfate Proteoglycans | 1 | 2008 | 9 | 0.070 |
Why?
|
| Onium Compounds | 2 | 2007 | 8 | 0.070 |
Why?
|
| Smad Proteins | 1 | 2008 | 18 | 0.070 |
Why?
|
| Potassium Cyanide | 1 | 2008 | 2 | 0.070 |
Why?
|
| Cardiovascular Agents | 1 | 2008 | 22 | 0.070 |
Why?
|
| Chiroptera | 1 | 2008 | 10 | 0.070 |
Why?
|
| Glycerol | 3 | 2016 | 17 | 0.070 |
Why?
|
| Electron Transport Chain Complex Proteins | 1 | 2008 | 12 | 0.070 |
Why?
|
| Neuroglia | 1 | 2008 | 30 | 0.070 |
Why?
|
| Energy Intake | 1 | 2008 | 69 | 0.070 |
Why?
|
| Mitochondria, Muscle | 1 | 2008 | 44 | 0.070 |
Why?
|
| Microscopy, Confocal | 1 | 2008 | 113 | 0.070 |
Why?
|
| Receptor, Cannabinoid, CB2 | 1 | 2007 | 2 | 0.070 |
Why?
|
| Leukocyte Rolling | 1 | 2007 | 7 | 0.070 |
Why?
|
| Mice, Inbred Strains | 1 | 2007 | 61 | 0.070 |
Why?
|
| Heart | 2 | 1999 | 232 | 0.070 |
Why?
|
| Cannabinoids | 1 | 2007 | 9 | 0.070 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2010 | 285 | 0.070 |
Why?
|
| Hypoglycemic Agents | 1 | 2008 | 110 | 0.070 |
Why?
|
| Renal Circulation | 1 | 2007 | 7 | 0.070 |
Why?
|
| Splanchnic Circulation | 1 | 2007 | 7 | 0.070 |
Why?
|
| Etanercept | 1 | 2007 | 6 | 0.070 |
Why?
|
| Pulse Wave Analysis | 2 | 2019 | 30 | 0.060 |
Why?
|
| Phosphoproteins | 2 | 2007 | 120 | 0.060 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2007 | 18 | 0.060 |
Why?
|
| Proteomics | 1 | 2008 | 197 | 0.060 |
Why?
|
| Thiocarbamates | 1 | 2006 | 6 | 0.060 |
Why?
|
| Pyrrolidines | 1 | 2006 | 11 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2019 | 897 | 0.060 |
Why?
|
| Transcription Factor AP-1 | 1 | 2006 | 26 | 0.060 |
Why?
|
| Pyrazoles | 1 | 2007 | 79 | 0.060 |
Why?
|
| Vitis | 1 | 2006 | 5 | 0.060 |
Why?
|
| Serotonin | 3 | 2003 | 16 | 0.060 |
Why?
|
| Gliosis | 3 | 2010 | 17 | 0.060 |
Why?
|
| Muscle Relaxation | 2 | 2006 | 3 | 0.060 |
Why?
|
| Fura-2 | 2 | 2003 | 10 | 0.060 |
Why?
|
| Plant Extracts | 1 | 2006 | 62 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 485 | 0.060 |
Why?
|
| Peroxynitrous Acid | 2 | 2002 | 7 | 0.060 |
Why?
|
| Brain Edema | 2 | 2016 | 21 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2013 | 257 | 0.060 |
Why?
|
| Fetus | 3 | 2013 | 79 | 0.060 |
Why?
|
| Oxygen Consumption | 2 | 2018 | 190 | 0.060 |
Why?
|
| Gestational Age | 3 | 2013 | 147 | 0.060 |
Why?
|
| Sex Factors | 2 | 2019 | 469 | 0.060 |
Why?
|
| Protein Binding | 1 | 2007 | 667 | 0.060 |
Why?
|
| Hand Strength | 2 | 2015 | 39 | 0.060 |
Why?
|
| Benzophenanthridines | 1 | 2004 | 8 | 0.050 |
Why?
|
| Alkaloids | 1 | 2004 | 16 | 0.050 |
Why?
|
| Staurosporine | 1 | 2004 | 10 | 0.050 |
Why?
|
| Captopril | 1 | 2004 | 9 | 0.050 |
Why?
|
| Citalopram | 2 | 2001 | 7 | 0.050 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2004 | 32 | 0.050 |
Why?
|
| Cytochrome P-450 Enzyme System | 2 | 2015 | 35 | 0.050 |
Why?
|
| Collagen | 2 | 2007 | 156 | 0.050 |
Why?
|
| Constriction, Pathologic | 2 | 2001 | 36 | 0.050 |
Why?
|
| Enzyme Activators | 1 | 2003 | 9 | 0.050 |
Why?
|
| Blood Flow Velocity | 1 | 2003 | 66 | 0.050 |
Why?
|
| Culture Techniques | 1 | 2003 | 12 | 0.050 |
Why?
|
| Calcium Channel Blockers | 2 | 2000 | 41 | 0.050 |
Why?
|
| Evidence-Based Medicine | 1 | 2004 | 146 | 0.050 |
Why?
|
| Glycolysis | 2 | 2014 | 96 | 0.050 |
Why?
|
| Green Fluorescent Proteins | 2 | 2014 | 101 | 0.050 |
Why?
|
| Apamin | 1 | 2002 | 2 | 0.050 |
Why?
|
| Charybdotoxin | 1 | 2002 | 2 | 0.050 |
Why?
|
| Incidence | 2 | 2017 | 572 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2002 | 88 | 0.050 |
Why?
|
| Deoxyguanosine | 1 | 2022 | 14 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2004 | 218 | 0.050 |
Why?
|
| Nimodipine | 1 | 2002 | 7 | 0.050 |
Why?
|
| Electric Conductivity | 1 | 2002 | 20 | 0.050 |
Why?
|
| Receptors, Thromboxane | 1 | 2002 | 1 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2002 | 6 | 0.050 |
Why?
|
| Gray Matter | 1 | 2022 | 24 | 0.050 |
Why?
|
| Phosphorylation | 1 | 2003 | 585 | 0.050 |
Why?
|
| Platelet Activation | 1 | 2002 | 55 | 0.050 |
Why?
|
| Osteoporosis | 2 | 2015 | 63 | 0.050 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 2021 | 11 | 0.050 |
Why?
|
| Gluconates | 2 | 2014 | 11 | 0.050 |
Why?
|
| Calcimycin | 1 | 2001 | 12 | 0.040 |
Why?
|
| Ionophores | 1 | 2001 | 6 | 0.040 |
Why?
|
| Myelin Sheath | 2 | 2013 | 28 | 0.040 |
Why?
|
| Purinones | 1 | 2001 | 2 | 0.040 |
Why?
|
| Academies and Institutes | 1 | 2021 | 16 | 0.040 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2001 | 12 | 0.040 |
Why?
|
| Nerve Degeneration | 2 | 2012 | 23 | 0.040 |
Why?
|
| Plaque, Amyloid | 1 | 2021 | 12 | 0.040 |
Why?
|
| Reaction Time | 1 | 2021 | 95 | 0.040 |
Why?
|
| Ileum | 1 | 2001 | 26 | 0.040 |
Why?
|
| Cyclic GMP | 1 | 2001 | 29 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2022 | 100 | 0.040 |
Why?
|
| Potassium Channel Blockers | 3 | 2010 | 10 | 0.040 |
Why?
|
| Prostaglandin H2 | 1 | 2000 | 1 | 0.040 |
Why?
|
| Cytophotometry | 1 | 2000 | 2 | 0.040 |
Why?
|
| Prefrontal Cortex | 1 | 2021 | 80 | 0.040 |
Why?
|
| Proteoglycans | 2 | 2013 | 38 | 0.040 |
Why?
|
| Nifedipine | 1 | 2000 | 12 | 0.040 |
Why?
|
| Antigens | 2 | 2013 | 68 | 0.040 |
Why?
|
| Bradykinin | 1 | 2000 | 27 | 0.040 |
Why?
|
| Body Composition | 2 | 2013 | 267 | 0.040 |
Why?
|
| Kinetics | 1 | 2001 | 553 | 0.040 |
Why?
|
| Lipid Peroxidation | 1 | 2000 | 48 | 0.040 |
Why?
|
| Pyrrolidinones | 1 | 2019 | 3 | 0.040 |
Why?
|
| Receptors, Prostaglandin E, EP4 Subtype | 1 | 2019 | 4 | 0.040 |
Why?
|
| Cell Death | 2 | 2010 | 119 | 0.040 |
Why?
|
| Tetrazoles | 1 | 2019 | 9 | 0.040 |
Why?
|
| Nitroarginine | 1 | 1999 | 4 | 0.040 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1999 | 31 | 0.040 |
Why?
|
| Nitroprusside | 1 | 1999 | 8 | 0.040 |
Why?
|
| Histamine | 1 | 1999 | 10 | 0.040 |
Why?
|
| Fibrin | 1 | 2019 | 17 | 0.040 |
Why?
|
| Lasers | 1 | 2019 | 68 | 0.040 |
Why?
|
| Sensorimotor Cortex | 1 | 2019 | 7 | 0.040 |
Why?
|
| NADPH Oxidase 2 | 2 | 2010 | 6 | 0.040 |
Why?
|
| Angiopoietin-2 | 2 | 2010 | 10 | 0.040 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2019 | 59 | 0.040 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 1998 | 4 | 0.040 |
Why?
|
| Pyridines | 1 | 2019 | 108 | 0.040 |
Why?
|
| Fatty Acids | 1 | 2000 | 221 | 0.040 |
Why?
|
| Amyloidogenic Proteins | 1 | 2018 | 7 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 996 | 0.040 |
Why?
|
| Urea | 1 | 2018 | 16 | 0.040 |
Why?
|
| Reversal Learning | 1 | 2018 | 8 | 0.040 |
Why?
|
| Action Potentials | 1 | 1999 | 196 | 0.040 |
Why?
|
| Ultrasonography | 2 | 2009 | 243 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2018 | 69 | 0.040 |
Why?
|
| Thyroid Nuclear Factor 1 | 1 | 2017 | 2 | 0.030 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2017 | 3 | 0.030 |
Why?
|
| Thiazoles | 1 | 2018 | 50 | 0.030 |
Why?
|
| Hypoxia, Brain | 1 | 2017 | 5 | 0.030 |
Why?
|
| Neural Stem Cells | 1 | 2017 | 13 | 0.030 |
Why?
|
| Tight Junction Proteins | 1 | 2017 | 9 | 0.030 |
Why?
|
| Ganglia | 1 | 2017 | 9 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 2017 | 23 | 0.030 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2017 | 16 | 0.030 |
Why?
|
| Receptors, LDL | 1 | 2017 | 28 | 0.030 |
Why?
|
| Tight Junctions | 1 | 2017 | 29 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2018 | 237 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2017 | 44 | 0.030 |
Why?
|
| Societies, Scientific | 1 | 2017 | 9 | 0.030 |
Why?
|
| Diet | 1 | 1999 | 241 | 0.030 |
Why?
|
| Hydroxyl Radical | 1 | 2017 | 7 | 0.030 |
Why?
|
| Fitness Trackers | 1 | 2017 | 11 | 0.030 |
Why?
|
| Actigraphy | 1 | 2017 | 22 | 0.030 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2009 | 43 | 0.030 |
Why?
|
| Community Health Services | 1 | 2017 | 33 | 0.030 |
Why?
|
| Nitrates | 2 | 2010 | 51 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2017 | 2426 | 0.030 |
Why?
|
| Intracranial Hypertension | 1 | 2016 | 6 | 0.030 |
Why?
|
| Retina | 1 | 2020 | 445 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2017 | 94 | 0.030 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2016 | 10 | 0.030 |
Why?
|
| Quinoxalines | 1 | 2016 | 17 | 0.030 |
Why?
|
| Nitriles | 1 | 2016 | 38 | 0.030 |
Why?
|
| Early Medical Intervention | 1 | 2015 | 7 | 0.030 |
Why?
|
| Batch Cell Culture Techniques | 1 | 2015 | 4 | 0.030 |
Why?
|
| Pyridones | 1 | 2016 | 36 | 0.030 |
Why?
|
| RANK Ligand | 1 | 2015 | 19 | 0.030 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2015 | 15 | 0.030 |
Why?
|
| Nanoconjugates | 1 | 2015 | 18 | 0.030 |
Why?
|
| Evoked Potentials, Somatosensory | 1 | 2015 | 14 | 0.030 |
Why?
|
| Postural Balance | 1 | 2015 | 41 | 0.030 |
Why?
|
| Receptor, Insulin | 1 | 2015 | 93 | 0.030 |
Why?
|
| Interleukin-12 Subunit p40 | 1 | 2014 | 8 | 0.030 |
Why?
|
| Stem Cell Niche | 1 | 2014 | 12 | 0.030 |
Why?
|
| Cerebral Infarction | 1 | 2014 | 26 | 0.030 |
Why?
|
| Hemoglobinometry | 1 | 2014 | 5 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 1 | 2014 | 49 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 302 | 0.030 |
Why?
|
| Dinoprost | 1 | 2014 | 9 | 0.030 |
Why?
|
| Ventricular Pressure | 1 | 2014 | 6 | 0.030 |
Why?
|
| Aldehydes | 1 | 2014 | 55 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 2014 | 74 | 0.030 |
Why?
|
| Interleukin-8 | 1 | 2013 | 45 | 0.030 |
Why?
|
| Hypoxia | 1 | 2014 | 90 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2014 | 106 | 0.030 |
Why?
|
| Rats, Inbred WKY | 1 | 2013 | 15 | 0.030 |
Why?
|
| Oklahoma | 1 | 2017 | 1053 | 0.030 |
Why?
|
| Chondroitin ABC Lyase | 1 | 2013 | 1 | 0.020 |
Why?
|
| Electron Transport Complex III | 1 | 2013 | 3 | 0.020 |
Why?
|
| Electron Transport Complex II | 1 | 2013 | 5 | 0.020 |
Why?
|
| Stroke Volume | 1 | 2014 | 124 | 0.020 |
Why?
|
| Basal Metabolism | 1 | 2013 | 11 | 0.020 |
Why?
|
| Electron Transport Complex I | 1 | 2013 | 13 | 0.020 |
Why?
|
| Ventricular Function, Left | 1 | 2014 | 115 | 0.020 |
Why?
|
| Oligodendroglia | 1 | 2013 | 17 | 0.020 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2013 | 51 | 0.020 |
Why?
|
| Superoxide Dismutase-1 | 1 | 2013 | 51 | 0.020 |
Why?
|
| Learning | 1 | 2013 | 100 | 0.020 |
Why?
|
| Biotransformation | 1 | 2012 | 9 | 0.020 |
Why?
|
| Health | 1 | 2012 | 12 | 0.020 |
Why?
|
| Sirtuin 3 | 1 | 2012 | 18 | 0.020 |
Why?
|
| Hydrazines | 2 | 2002 | 13 | 0.020 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 2 | 2002 | 52 | 0.020 |
Why?
|
| Mammals | 1 | 2012 | 48 | 0.020 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2012 | 28 | 0.020 |
Why?
|
| Fatty Acids, Unsaturated | 2 | 2002 | 68 | 0.020 |
Why?
|
| Hindlimb Suspension | 1 | 2011 | 8 | 0.020 |
Why?
|
| Exploratory Behavior | 1 | 2011 | 12 | 0.020 |
Why?
|
| Inhibitor of Differentiation Proteins | 1 | 2011 | 11 | 0.020 |
Why?
|
| Pancreas | 1 | 2011 | 63 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2011 | 118 | 0.020 |
Why?
|
| Linear Models | 1 | 2011 | 202 | 0.020 |
Why?
|
| Microdissection | 1 | 2010 | 15 | 0.020 |
Why?
|
| Receptors, Prostaglandin E, EP1 Subtype | 1 | 2010 | 2 | 0.020 |
Why?
|
| Cyclooxygenase 1 | 1 | 2010 | 9 | 0.020 |
Why?
|
| Neuropilin-1 | 1 | 2010 | 5 | 0.020 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2010 | 8 | 0.020 |
Why?
|
| Caspases | 1 | 2010 | 43 | 0.020 |
Why?
|
| DNA, Complementary | 1 | 2010 | 78 | 0.020 |
Why?
|
| Cyclooxygenase 2 | 1 | 2010 | 68 | 0.020 |
Why?
|
| Interleukin-1beta | 1 | 2010 | 46 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2010 | 68 | 0.020 |
Why?
|
| Myocytes, Cardiac | 1 | 2010 | 64 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2010 | 115 | 0.020 |
Why?
|
| Gene Transfer Techniques | 1 | 2010 | 74 | 0.020 |
Why?
|
| Diffuse Axonal Injury | 1 | 2009 | 1 | 0.020 |
Why?
|
| Movement Disorders | 1 | 2009 | 4 | 0.020 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2009 | 22 | 0.020 |
Why?
|
| Hypertrophy | 1 | 2009 | 46 | 0.020 |
Why?
|
| Ethidium | 1 | 2009 | 6 | 0.020 |
Why?
|
| Acridines | 1 | 2009 | 3 | 0.020 |
Why?
|
| Luminescence | 1 | 2009 | 9 | 0.020 |
Why?
|
| Rats, Zucker | 1 | 2009 | 2 | 0.020 |
Why?
|
| Cell Extracts | 1 | 2009 | 14 | 0.020 |
Why?
|
| Dehydroepiandrosterone | 1 | 2009 | 15 | 0.020 |
Why?
|
| Enoyl-CoA Hydratase | 1 | 2008 | 4 | 0.020 |
Why?
|
| Aconitate Hydratase | 1 | 2008 | 4 | 0.020 |
Why?
|
| Perfusion | 1 | 2009 | 43 | 0.020 |
Why?
|
| omega-N-Methylarginine | 1 | 2008 | 11 | 0.020 |
Why?
|
| Proteins | 1 | 2011 | 254 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2008 | 55 | 0.020 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2010 | 136 | 0.020 |
Why?
|
| Food, Formulated | 1 | 2008 | 11 | 0.020 |
Why?
|
| Food Deprivation | 1 | 2008 | 11 | 0.020 |
Why?
|
| Collagen Type IV | 1 | 2008 | 7 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2008 | 124 | 0.020 |
Why?
|
| Laminin | 1 | 2008 | 21 | 0.020 |
Why?
|
| Fibronectins | 1 | 2008 | 28 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2009 | 135 | 0.020 |
Why?
|
| NADPH Dehydrogenase | 1 | 2008 | 4 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2010 | 466 | 0.020 |
Why?
|
| Glycoproteins | 1 | 2009 | 124 | 0.020 |
Why?
|
| Autopsy | 1 | 2007 | 26 | 0.020 |
Why?
|
| Antigens, CD34 | 1 | 2007 | 14 | 0.020 |
Why?
|
| Sphingosine | 1 | 2007 | 22 | 0.020 |
Why?
|
| Cadherins | 1 | 2007 | 24 | 0.020 |
Why?
|
| Receptor, Cannabinoid, CB1 | 1 | 2007 | 2 | 0.020 |
Why?
|
| Platelet-Rich Plasma | 1 | 2007 | 8 | 0.020 |
Why?
|
| Adenosine Diphosphate | 1 | 2007 | 27 | 0.020 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2007 | 33 | 0.020 |
Why?
|
| Luminescent Measurements | 1 | 2007 | 31 | 0.020 |
Why?
|
| Platelet Function Tests | 1 | 2007 | 24 | 0.020 |
Why?
|
| Aborted Fetus | 1 | 2007 | 2 | 0.020 |
Why?
|
| Celecoxib | 1 | 2007 | 10 | 0.020 |
Why?
|
| Lysophospholipids | 1 | 2007 | 51 | 0.020 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2007 | 60 | 0.020 |
Why?
|
| Survival Rate | 1 | 2008 | 432 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2007 | 190 | 0.020 |
Why?
|
| Apoptosis Inducing Factor | 1 | 2006 | 2 | 0.020 |
Why?
|
| Wine | 1 | 2006 | 4 | 0.020 |
Why?
|
| Chromatography, Affinity | 1 | 2006 | 32 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2007 | 157 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2006 | 44 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2006 | 104 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 2004 | 18 | 0.010 |
Why?
|
| Metalloendopeptidases | 1 | 2004 | 40 | 0.010 |
Why?
|
| Androsterone | 1 | 2003 | 1 | 0.010 |
Why?
|
| Tetraethylammonium | 1 | 2003 | 2 | 0.010 |
Why?
|
| Adenylyl Cyclase Inhibitors | 1 | 2003 | 2 | 0.010 |
Why?
|
| Dithiothreitol | 1 | 2003 | 5 | 0.010 |
Why?
|
| Soluble Guanylyl Cyclase | 1 | 2003 | 2 | 0.010 |
Why?
|
| Calcium-Transporting ATPases | 1 | 2003 | 9 | 0.010 |
Why?
|
| Potassium Chloride | 1 | 2003 | 11 | 0.010 |
Why?
|
| Teratogens | 1 | 2003 | 4 | 0.010 |
Why?
|
| Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2003 | 18 | 0.010 |
Why?
|
| Glutathione Disulfide | 1 | 2003 | 14 | 0.010 |
Why?
|
| Guanylate Cyclase | 1 | 2003 | 15 | 0.010 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2003 | 24 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2004 | 194 | 0.010 |
Why?
|
| NADP | 1 | 2003 | 39 | 0.010 |
Why?
|
| Vascular Patency | 1 | 2002 | 44 | 0.010 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2002 | 45 | 0.010 |
Why?
|
| 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt | 1 | 2002 | 3 | 0.010 |
Why?
|
| Xanthine Oxidase | 1 | 2002 | 5 | 0.010 |
Why?
|
| Multienzyme Complexes | 1 | 2002 | 29 | 0.010 |
Why?
|
| Nitrites | 1 | 2002 | 30 | 0.010 |
Why?
|
| DNA | 1 | 2004 | 378 | 0.010 |
Why?
|
| Arginine | 1 | 2002 | 42 | 0.010 |
Why?
|
| Prostaglandins | 1 | 2002 | 13 | 0.010 |
Why?
|
| Cattle | 1 | 2003 | 389 | 0.010 |
Why?
|
| Sodium Channel Blockers | 1 | 1999 | 11 | 0.010 |
Why?
|
| Atrial Function, Left | 1 | 1999 | 4 | 0.010 |
Why?
|
| Sodium Channels | 1 | 1999 | 8 | 0.010 |
Why?
|
| Ventricular Function, Right | 1 | 1999 | 13 | 0.010 |
Why?
|
| Papillary Muscles | 1 | 1999 | 15 | 0.010 |
Why?
|
| Electrophysiology | 1 | 1999 | 150 | 0.010 |
Why?
|
| Depressive Disorder | 1 | 1998 | 56 | 0.010 |
Why?
|